Covid-19 roundup: CureVac finds big vaccine partner in Bayer; Slaoui will stay on as Biden consultant
Aside from donating chloroquine in the early days of the pandemic, Bayer has largely stayed out of the spotlight as other Big Pharmas deal and invest their way into leading roles in developing Covid-19 vaccines and therapeutics.
But that’s changing today as Bayer puts its weight behind CureVac, a fellow German player, and its mRNA vaccine candidate.
The companies are entering a “collaboration and services agreement,” which will see Bayer take up responsibilities in development, supply and key territory operations — leveraging its expertise in areas like clinical operations, regulatory affairs, pharmacovigilance, supply chain and on-the-ground infrastructure in certain countries.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
